In today’s briefing:
- Fulcrum Therapeutics: Why Is There An Acquisition Interest Despite $80M Losmapimod Setback!
Fulcrum Therapeutics: Why Is There An Acquisition Interest Despite $80M Losmapimod Setback!
- Fulcrum Therapeutics reported its financial results and business developments for the third quarter of 2024 and reported that it is realigning its focus towards the advancement of pociredir, an oral HbF inducer intended for the treatment of sickle cell disease, and its preclinical pipeline.
- Previously, Fulcrum Therapeutics had been developing losmapimod for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
- However, the Phase III REACH trial did not demonstrate a significant difference between losmapimod and placebo on the primary or key secondary endpoints.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
